Intervention
GV20-0251
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownA Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · 2025-09-04
RECRUITINGStudy of GV20-0251 in Participants With Solid Tumor MalignanciesNCT07070518 · 2025-07-11
RECRUITINGA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesNCT05669430 · 2023-03-23
RECRUITINGA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.NCT07623642 · 2026-06-02
NOT_YET_RECRUITINGCommon conditions
Cholangiocarcinoma2Endometrial Carcinoma (EC)2HCC - Hepatocellular Carcinoma2Melanoma2Non-Small Cell Lung Cancer2Pancreatic Ductal Adenocarcinoma2pMMR/MSS Adenocarcinoma of the Colon or Rectum2Squamous Head and Neck Carcinoma2Adult Refractory Cancer1Carcinoma, Non-Small-Cell Lung1Colorectal Neoplasms1Cutaneous Melanoma1Endometrial Cancer1Esophageal Squamous Cell Carcinoma1Gallbladder Neoplasms1HNSCC1NSCLC (Non-small Cell Lung Cancer)1Prostatic Neoplasms1Refractory Cancer1Small Cell Lung Cancer1Small Cell Lung Carcinoma1Solid Tumor Cancer1Solid Tumor, Adult1Squamous Cell Carcinoma of Head and Neck1Testicular Cancer1
Leading sponsors
Trial status mix
RECRUITING3
NOT_YET_RECRUITING1
Phase mix
PHASE13
PHASE23
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.